Free Trial
→ The chokepoint supplier behind SpaceX's $1.75 trillion empire (From Behind the Markets) (Ad)tc pixel
NYSEAMERICAN:MAIA

MAIA Biotechnology Q3 2025 Earnings Report

MAIA Biotechnology logo
$1.35 -0.04 (-2.88%)
Closing price 05/6/2026 04:10 PM Eastern
Extended Trading
$1.36 +0.01 (+1.11%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings History

MAIA Biotechnology EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.19
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

MAIA Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MAIA Biotechnology Announcement Details

Quarter
Q3 2025
Date
11/7/2025
Time
Before Market Opens
Conference Call Date
Friday, November 7, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

MAIA Biotechnology's Q1 2026 earnings is estimated for Friday, May 8, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

MAIA Biotechnology's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

MAIA Biotechnology Earnings Headlines

MAIA Biotechnology (MAIA) to Release Earnings on Friday
May 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30750731
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
April 16, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/maia-biotechnology-activates-first-u-s-site-for-ongoing-international-phase-2-expansion-trial-of-novel-telomere-targeting-treatment-targeting-advanced-non-small-cell-lung-cancer-1036029197
Nobody Understands Why Trump Is Invading Iran (here’s the answer)
Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.tc pixel
 |  Banyan Hill Publishing (Ad)
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
April 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/08/3270148/0/en/maia-biotechnology-expects-recent-33-million-capital-raise-to-fully-fund-ongoing-pivotal-phase-3-trial-of-novel-telomere-targeting-anticancer-therapy.html
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265650/0/en/maia-biotechnology-reports-overall-survival-exceeding-two-years-for-eight-patients-in-ongoing-phase-2-clinical-trial-in-non-small-cell-lung-cancer.html
MAIA Biotechnology (MAIA) price target increased by 18.16% to 12.38
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/maia-biotechnology-maia-price-target-increased-by-1816-to-1238/ar-AA1ZwYgd
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods. In parallel, MAIA Biotechnology is advancing therapeutic constructs that couple monoclonal antibodies to therapeutic radioisotopes for selective tumor cell eradication. These efforts are supported by in‐house radiochemistry capabilities and collaborative research partnerships with academic institutions.

Headquartered in the United States, MAIA Biotechnology serves both domestic and international research markets and is preparing key assets for regulatory submission and first‐in‐human trials. The management team comprises industry veterans in radiopharmaceutical development and antibody engineering, and the company continues to expand its platform technology to address unmet needs in cancer diagnosis and treatment.

View MAIA Biotechnology Profile
Earnings Tools